NCT05623995View on ClinicalTrials.gov

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions
In-stent RestenosisMajor Adverse Cardiovascular Events
Interventions
DRUG

PCSK9 inhibitor

Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..

DRUG

Statin

Guideline recommended statin therapy.

Trial Locations (1)

100029

RECRUITING

Beijing Anzhen Hospital, Beijing

All Listed Sponsors
lead

Lin Zhao

OTHER